Table 3.
Comparison of genotype and allele frequencies of genes between CHD cases and non-CHD controls by gender
| Group | Gene (SNP, allele) | Genotype counts (Cases vs. Controls) | Genotype (χ2, P) | Allele (χ2, P) | OR (95% CI) |
|---|---|---|---|---|---|
| Male | |||||
| APOE (rs7259620, G/A) | 283/217/37 vs. 199/171/51 | 8.397, 0.015 | 5.190, 0.023 | 1.258 (1.032-1.533) | |
| CETP (rs4783961, G/A) | 322/195/17 vs. 252/144/23 | N.S. | N.S. | N.S. | |
| MLXIPL (rs35493868, G/C) | 410/113/9 vs. 345/70/3 | N.S. | N.S. | N.S. | |
| APOA5 (rs10750097, G/A) | 163/261/114 vs. 145/194/82 | N.S. | N.S. | N.S. | |
| PCSK9 (rs2479409, G/A) | 273/227/38 vs. 207/173/40 | N.S. | N.S. | N.S. | |
| SCARB1 (rs59358115, G/A) | 404/123/11 vs. 310/104/7 | N.S. | N.S. | N.S. | |
| PRKAG1 (rs2293446, G/A) | 186/250/97 vs. 152/196/71 | N.S. | N.S. | N.S. | |
| PON3 (rs11770903, A/G) | 374/148/15 vs. 298/114/9 | N.S. | N.S. | N.S. | |
| LEP (rs13228377, A/G) | 315/196/27 vs. 243/152/26 | N.S. | N.S. | N.S. | |
| ANGPTL4 (rs4076317, C/G) | 259/234/39 vs. 218/171/29 | N.S. | N.S. | N.S. | |
| LEPR (rs6656451, C/T) | 463/67/3 vs. 372/45/1 | N.S. | N.S. | N.S. | |
| ANGPTL3 (rs11207997, C/T) | 311/196/24 vs. 253/138/26 | N.S. | N.S. | N.S. | |
| VLDLR (rs7852409, C/G) | 379/139/20 vs. 295/105/17 | N.S. | N.S. | N.S. | |
| PPAP2B (rs72664392, T/C) | 410/117/9 vs. 326/86/9 | N.S. | N.S. | N.S. | |
| PON2 (rs12704796, G/A) | 217/242/79 vs. 147/221/52 | HWD in controls | N.A. | N.A. | |
| ADIPOQ (rs266729, C/G) | 261/226/46 vs. 227/155/37 | N.S. | N.S. | N.S. | |
| ADIPOR1 (rs7523903, C/G) | 331/185/18 vs. 251/156/12 | HWD in controls | N.A. | N.A. | |
| Female | |||||
| APOE (rs7259620, G/A) | 123/105/18 vs. 154/137/26 | N.S. | N.S. | N.S. | |
| CETP (rs4783961, G/A) | 145/86/12 vs. 200/96/16 | N.S. | N.S. | N.S. | |
| MLXIPL (rs35493868, G/C) | 187/55/1 vs. 242/65/4 | N.S. | N.S. | N.S. | |
| APOA5 (rs10750097, G/A) | 72/117/57 vs. 91/161/64 | N.S. | N.S. | N.S. | |
| PCSK9 (rs2479409, G/A) | 119/99/28 vs. 151/143/23 | N.S. | N.S. | N.S. | |
| SCARB1 (rs59358115, G/A) | 179/63/4 vs. 236/74/8 | N.S. | N.S. | N.S. | |
| PRKAG1 (rs2293446, G/A) | 84/112/47 vs. 127/135/50 | N.S. | N.S. | N.S. | |
| PON3 (rs11770903, A/G) | 167/70/9 vs. 227/83/7 | N.S. | N.S. | N.S. | |
| LEP (rs13228377, A/G) | 135/100/11 vs. 173/127/17 | N.S. | N.S. | N.S. | |
| ANGPTL4 (rs4076317, C/G) | 1135/88/19 vs. 143/144/25 | N.S. | N.S. | N.S. | |
| LEPR (rs6656451, C/T) | 215/26/2 vs. 277/35/0 | N.S. | N.S. | N.S. | |
| ANGPTL3 (rs11207997, C/T) | 134/95/13 vs. 190/106/15 | N.S. | N.S. | N.S. | |
| VLDLR (rs7852409, C/G) | 167/69/9 vs. 218/85/13 | N.S. | N.S. | N.S. | |
| PPAP2B (rs72664392, T/C) | 241/64/12 vs. 173/71/2 | 9.878, 0.007 | N.S. | N.S. | |
| PON2 (rs12704796, G/A) | 88/124/34 vs. 102/167/49 | N.S. | N.S. | N.S. | |
| ADIPOQ (rs266729, C/G) | 138/90/15 vs. 174/108/30 | HWD in controls | N.A. | N.A. | |
| ADIPOR1 (rs7523903, C/G) | 143/92/7 vs. 197/94/21 | HWD in controls | N.A. | N.A. |
*PCSK9 - proprotein convertase subtilisin/kexin type 9; PPAP2B - phosphatidic acid phosphatase type 2B; ANGPTL3 - angiopoietin-like 3; LEPR - leptin receptor; ADIPOR1 - adiponectin receptor 1; ADIPOQ - adiponectin; MLXIPL - MLX-interacting protein-like; PON3 - paraoxonase 3; PON2 - paraoxonase 2; LEP - leptin; VLDLR - very-low-density-lipoprotein receptor; APOA5 - apolipoprotein A-V; PRKAG1 - 5’-AMP-activated protein kinase subunit gamma-1; SCARB1 - scavenger receptor class B type 1; CETP - cholesteryl ester transfer protein; ANGPTL4 - angiopoietin-like 4; APOE - apolipoprotein E. Genotypic distributions of PON2 rs12704796 in males, ADIPOQ rs266729 in females, and ADIPOR1 rs7523903 did not meet HWE in the male controls, female controls, and both male and female controls, respectively. N.S. - not significant; N.A. - not analyzed; HWD in controls: did not meet HWE in the controls; 95% CI - 95% confidence interval; OR - odds ratio. APOE (rs7259620, G/A) was significant in males under recessive model [GG+GA vs AA, χ2=19.3, P<0.0001, OR (95% CI)=2.65 (1.69-4.15)].